TGFB2 gene methylation predicts improved OS in adult GBM patients that is age and sex-dependent, and correlation with mRNA identifies Reactome pathways that could potentially remodel the tumor microenvironment to augment T-cell activation and antigen processing, which would be potentially beneficial to patient survival for those undergoing immune therapies. The gene discussed is TGFB2; the disease is neoplasm.